Athira Pharma, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark J. Litton
- Full Time Employees
- 26
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18706 North Creek Parkway Bothell WA United States of America 98011
- IPO Date
- Sep 18, 2020
- CIK
- 0001620463
- Website
- athira.com
- Similar Companies
- Business
- Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company focused on developing small molecule therapies that modulate the neurotrophic hepatocyte growth factor (HGF) system to restore neuronal health, promote neuroprotection, and slow neurodegeneration in diseases such as Alzheimer's disease (AD), Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), and amyotrophic lateral sclerosis (ALS); its lead pipeline candidates include ATH-1105, an oral small molecule in Phase 1 clinical trials for ALS with dosing of patients expected in 2025 and preclinical data demonstrating improvements in motor function, nerve function, and biomarkers of neurodegeneration and inflammation, fosgonimeton, a subcutaneously administered small molecule previously evaluated in the Phase 2/3 LIFT-AD trial for mild-to-moderate AD (topline results announced August 2024), the Phase 2 ACT-AD exploratory trial for AD, and the Phase 2 SHAPE trial for PDD and DLB, ATH-1020, an oral small molecule that completed Phase 1 trials with a favorable safety profile and preclinical efficacy in diabetic neuropathy pain models, and several preclinical compounds targeting neurodegenerative indications. Founded in 2011 and headquartered in Bothell, Washington, the company operates primarily in the United States with global clinical trial sites and targets patients with neurodegenerative disorders through its proprietary drug discovery platform. Recent strategic developments include a September 2024 decision to prioritize ATH-1105 advancement following LIFT-AD topline results and completion of its first Phase 1 cohort in May 2024, a 10-for-1 reverse stock split in September 2025 to meet Nasdaq listing requirements, ongoing exploration of strategic alternatives such as partnerships, mergers, or acquisitions advised by Cantor Fitzgerald & Co., presentation of preclinical data on ATH-1105 neuroprotective effects at the 2024 Motor Neurone Disease Association Symposium and fosgonimeton mechanisms at the 2024 Alzheimer's Association International Conference, and cash reserves of $51.3 million as of December 31, 2024, expected to fund operations for at least the next 12 months amid plans for additional financing.
ATHA Energy Announces Corporate Activities Update
ATHA Energy Reports Widest Intersection to Date at Rib North Discovery with 37 m of Composite Uranium Mineralization in Ribn-DD-003 – Multiple Drillholes Demonstrating Continuity of Uranium Mineralization
ATHA Energy Makes Major New High-Grade Discovery along the Lac 50 Corridor - Intersects 11.5 m of Composite Uranium Mineralization Including 1.6 m of Near Continuous High-Grade 4 km Along Strike from Lac 50 Deposit Area
OTC Markets Group Welcomes ATHA Energy Corp. to OTCQX
Athena Gold Provides Exploration Update from Excelsior Springs, Nevada
Athena Provides Updates Across Gold Portfolio
Athena Provides Exploration Update from Laird Lake, Reports Assays from Hole 1 and Visible Gold in Hole 5
Athena Reports Further Encouraging Visual Results from Holes 2 and 3 at Laird Lake
Atha Energy Completes Mobilization & Commences Diamond Drilling Operations as Part of the 2026 Angilak Exploration Program – Fully Funded and Largest to Date at the Project
ATHA Energy Announces Filing Of Annual Financial Statements, MD&A And Annual Information Form And Election To Issue Common Shares In Satisfaction Of US$25 Million Convertible Debenture Interest Payment Obligations
Athena Gold Awarded $200,000 Grant from Ontario Government
ATHA Energy Initiates Ongoing Site Mobilization in Advance Of 2026 Angilak Exploration Program - Exploration Activities Commencing in April
Athena Gold Announces Share Consolidation
Reviewing Athira Pharma (NASDAQ:ATHA) & InflaRx (NASDAQ:IFRX)
Athena Gold Provides Exploration Update From Excelsior Springs, Nevada
Athena Completes Acquisition of Forester Gold Project Near Orla Mining's Musselwhite Mine
Athena To Acquire Forester Gold Project, Near Orla Mining's Musselwhite Mine in Northwestern Ontario
BML Capital Management LLC Has $1.34 Million Stock Position in Athira Pharma, Inc. $ATHA
Head-To-Head Contrast: Alterity Therapeutics (NASDAQ:ATHE) & Athira Pharma (NASDAQ:ATHA)
ATHA Energy Provides Post CAD $63 Million Financing Plans - Focused on Growth and Discovery at the Angilak Uranium Project